Advice
Following an abbreviated submission
Tablets delivering a fixed dose combination of abacavir 600mg and lamivudine 300mg are accepted for use in NHS Scotland for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adults and adolescents over 12 years, in combination with other antiretroviral medicinal products. Both products are nucleoside reverse transcriptase inhibitors.
In patients for whom this combination is appropriate, it offers a single tablet at a lower cost per dose compared with the individual components.
Download detailed advice27KB (PDF)
Medicine details
- Medicine name:
- Abacavir/lamivudine combination (Kivexa®)
- SMC ID:
- 175/05
- Indication:
- HIV-1
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 09 May 2005